- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Boehringer Ingelheim
Ingelheim, Germany. Friday 25 April 2008
Monotherapy treatment with the triple angiokinase inhibitor1 BIBF 1120* offers promising efficacy and is well tolerated in patients with advanced, relapsed non-small cell lung cancer (NSCLC), according to results from a phase II study in patients with lung cancer2. Of particular note were results from a subset of 57 patients with „good disease state? (ECOG performance status of 0 or 1): these patients experienced longer overall survival (median overall survival was 9.5 months), longer progression-free survival (PFS; median PFS was 2.9 months) and a higher stable disease rate of 59% compared with the overall study population. The results were presented today by Dr Joachim von Pawel from Asklepios Fachkliniken München-Gauting, Germany, at the 1st European Lung Cancer Conference jointly organized by IASLC and ESMO in Geneva, Switzerland.
*BIBF 1120 is an investigational compounds. Its safety and efficacy has not yet been fully established.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
